• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:58:54 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OBSV alert in real time by email
    SC 13G/A 1 d8800329_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    ObsEva SA
    (Name of Issuer)

     

     

    Common Shares, par value CHF 0.0769 per share
    (Title of Class of Securities)

     

     

    H5861P103
    (CUSIP Number)

     

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)

     

    [_] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    CUSIP No H5861P103    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Armistice Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,889,432    
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,889,432    
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,889,432    
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.99%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    IA, OO

     

     
     
     

     

     

    CUSIP No H5861P103    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Steven Boyd  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,889,432    
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,889,432    
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,889,432    
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.99%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    IN, HC

     

     
     
     

     

    CUSIP No H5861P103    

     

           
    Item 1. (a). Name of Issuer:  
           
        ObsEva SA  
           
      (b). Address of Issuer's Principal Executive Offices:  
           
       

    Chemin des Aulx, 12

    1228 Plan-les-Ouates

    Geneva, Switzerland

     
           
           
    Item 2. (a). Name of Person Filing:  
           
       

    Armistice Capital, LLC

    Steven Boyd

     
           
      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     
           
      (c) Citizenship:  
           
       

    Armistice Capital, LLC – Delaware

    Steven Boyd – United States of America

     
           
      (d).   Title of Class of Securities:  
           
        Common Shares, par value CHF 0.0769 per share  
     

     

     

       
      (e). CUSIP Number:  
           
        H5861P103  

     

     


    Item 3.
      If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
           
      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

     

     

    Item 4. Ownership.
     
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)   Amount beneficially owned:
         
       

    Armistice Capital, LLC – 2,889,432

    Steven Boyd – 2,889,432

         
      (b)   Percent of class:
         
       

    Armistice Capital, LLC – 4.99%

    Steven Boyd – 4.99%

         

     

      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote    
         

     

    Armistice Capital, LLC – 0

    Steven Boyd – 0

     

     
        (ii)   Shared power to vote or to direct the vote    
         

     

    Armistice Capital, LLC – 2,889,432

    Steven Boyd – 2,889,432

      

     
        (iii) Sole power to dispose or to direct the disposition of    
         

     

    Armistice Capital, LLC – 0

    Steven Boyd – 0

     

     
        (iv)   Shared power to dispose or to direct the disposition of    
         

     

    Armistice Capital, LLC – 2,889,432

    Steven Boyd – 2,889,432

     
                 

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
       
       

     

     

     
     
     

     

     

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      Armistice Capital Master Fund Ltd., a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, LLC, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
     

     

     

    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
     

     

     

    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
     

     

     

    Item 10. Certification.
       

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 16, 2021
      (Date)

     

     

      Armistice Capital, LLC
       
      By:  /s/ Steven Boyd
      Steven Boyd
      Managing Member
     

     

     

      /s/ Steven Boyd
      Steven Boyd

     

     

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

     

    Exhibit A

    AGREEMENT

     

    The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 16, 2021 relating to the Common Shares, par value CHF 0.0769 per share, of ObsEva SA shall be filed on behalf of the undersigned.

     

      Armistice Capital, LLC
       
      By:  /s/ Steven Boyd
      Steven Boyd
      Managing Member
     

     

     

      /s/ Steven Boyd
      Steven Boyd

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $OBSV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OBSV

    DatePrice TargetRatingAnalyst
    8/30/2022Buy → Neutral
    H.C. Wainwright
    6/3/2022$6.00Overweight
    Cantor Fitzgerald
    4/26/2022$12.00Buy
    Canaccord Genuity
    3/28/2022$12.00Buy
    Aegis Capital
    11/29/2021$17.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $OBSV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ObsEva Files Year End 2022 Financial Statements

      ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing and commercializing novel therapies to improve women's health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be accessed in the financial section of the Company's website, here or directly via the link here. ObsEva expects to publish its Swiss Annual Report to Shareholders, including the financial results for year end 20

      3/31/23 4:01:00 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasd

      3/15/23 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

      3/13/23 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    SEC Filings

    See more
    • SEC Form 15-12G filed by ObsEva SA

      15-12G - ObsEva SA (0001685316) (Filer)

      4/26/23 7:00:50 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva SA filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - ObsEva SA (0001685316) (Filer)

      4/11/23 4:01:29 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by ObsEva SA

      10-K - ObsEva SA (0001685316) (Filer)

      3/31/23 4:01:50 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Financials

    Live finance-specific insights

    See more
    • ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

      -Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial- -Linzagolix franchise: Announced licensing agreement with Theramex to support commercialization in Europe, in addition to relationship with Syneos Health to support commercialization in the United States- Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange                 GENEVA, Switzerland – May 17, 2022 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharma

      5/17/22 7:00:00 AM ET
      $OBSV
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

      GENEVA, Switzerland – May 12, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it plans to host a conference call on Tuesday, May 17, 2022, at 8:00 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update. Individuals may participate via telephone by dialling (877) 300-8521 (domestic) or +1 (412) 317-6026 (international) and using conference ID 10166576. The webcast can be accessed live here and will also be accessible under "Events Calendar" in the investors section of ObsEva's website. The webcast will be archived on the company

      5/12/22 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

      -Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months- -Once daily linzagolix 75 mg without ABT demonstrated statistically significant improvement for dysmenorrhea versus placebo and showed improvement but did not meet the co-primary objective of reduction in non-menstrual pelvic pain at 3 months; also showed improvement in sec

      1/6/22 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ObsEva downgraded by H.C. Wainwright

      H.C. Wainwright downgraded ObsEva from Buy to Neutral

      8/30/22 7:29:47 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on ObsEva with a new price target

      Cantor Fitzgerald initiated coverage of ObsEva with a rating of Overweight and set a new price target of $6.00

      6/3/22 7:29:31 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on ObsEva with a new price target

      Canaccord Genuity initiated coverage of ObsEva with a rating of Buy and set a new price target of $12.00

      4/26/22 6:26:53 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Loumaye Ernest

      4 - ObsEva SA (0001685316) (Issuer)

      4/11/23 4:02:23 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Loumaye Ernest bought $440,000 worth of shares (4,000,000 units at $0.11), increasing direct ownership by 200% to 6,000,000 units

      4 - ObsEva SA (0001685316) (Issuer)

      3/2/23 4:16:42 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brown William Michael

      4 - ObsEva SA (0001685316) (Issuer)

      2/24/23 4:50:38 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Leadership Updates

    Live Leadership Updates

    See more
    • ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

      3/13/23 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

      GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company's Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva's Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to step down from the role of Chair and retire from the Board of Directors, effective following the conclusion of the Annual General Meeting. "We could not be more pleased, or fortunate, to have

      5/19/22 7:05:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company's Executive Committee, effective May 9, 2022. Dr. Howard, who brings to ObsEva more than 20 years of women's health expertise, will be responsible for the Company's clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new opportunity. To help ensure a smooth tra

      5/2/22 7:00:00 AM ET
      $EVFM
      $OBSV
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by ObsEva SA

      SC 13D - ObsEva SA (0001685316) (Subject)

      4/17/23 5:00:00 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ObsEva SA (Amendment)

      SC 13G/A - ObsEva SA (0001685316) (Subject)

      2/14/23 4:18:58 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed

      SC 13D/A - ObsEva SA (0001685316) (Subject)

      3/4/21 6:13:21 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care